Clinical Trial Update: Pembrolizumab With or Without Axitinib for Clear Cell Kidney Cancer in Patients Undergoing Surgery [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating pembrolizumab with or without axitinib for clear cell renal cell carcinoma in patients undergoing surgery was terminated, with result…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Clear Cell Renal Cell Carcinoma

Drugs mentioned

• Axitinib (Axitinib)
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: University of California, San Francisco | Conditions: Metastatic Clear Cell Renal Cell Carcinoma, Recurrent Clear Cell Renal Cell Carcinoma | Phase 2 | Status: TERMINATED | Results posted: 2025-11-05